EU competition regulators are likely to issue an order for Illumina (ILMN) to sell cancer detection test maker Grail as soon as next week, reports the Financial Times. llumina and EU regulators in Brussels have been in legal wranglings since Illumina “completed the purchase of Grail even as EU regulators were still examining whether the deal would hurt competition,” added the FT.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ILMN:
- Illumina (NASDAQ:ILMN) Slips as EU Regulators Move against It
- GRAIL LLC announces findings from multi-cancer detection blood test
- Illumina removed from ‘Tactical Outperform’ list, target lowered at Evercore ISI
- Buy/Sell: Wall Street’s top 10 stock calls this week
- Illumina price target lowered to $170 from $230 at HSBC